1. Research Progress on Influencing Factors of Graves’ Disease Recurrence Treated with Antithyroid Drugs
   潇潇 何, 2023, Advances in Clinical Medicine CrossRef
2. Evaluation of YouTube As A Source For Graves' Disease Information: Is High‐Quality Guideline‐Based Information Available?
   Oluwatobiloba Ayo‐Ajibola et al, 2024, OTO Open CrossRef
3. A retrospective analysis of 1,231 patients with anemia after surgical treatment of hyperthyroidism
   Ruisha Tu et al, 2018, Experimental and Therapeutic Medicine CrossRef
4. Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study
   Xinpan Wang et al, 2024, Journal of Translational Medicine CrossRef
5. The Influence of Juvenile Graves’ Ophthalmopathy on Graves’ Disease Course
   Jurate Jankauskiene et al, 2017, Journal of Ophthalmology CrossRef
6. Pharmacological Survey of Graves' Disease: A Mini Review
   Akhtar Saifi et al, 2021, Journal of Clinical and Basic Research CrossRef
7. Analysis of Related Factors in Refractory Graves’ Disease
   鑫 王, 2023, Advances in Clinical Medicine CrossRef
8. Graves’ Disease
   Josephine H. Li et al, 2019, The Thyroid and Its Diseases CrossRef
9. Adjunctive bile acid sequestrant therapy for hyperthyroidism in adults
   Carlos A Salazar et al, 2016, Cochrane Database of Systematic Reviews CrossRef
10. Graves’ Disease in Senegal: Clinical and Evolutionary Aspects
    A. Sarr et al, 2016, Open Journal of Internal Medicine CrossRef
11. Predictive effect of antithyroid antibody for relapse of Graves' disease
    Kazuko Yoshizawa et al, 2022, Pediatrics International CrossRef
12. The activity of NAD- and NAD(P)-dependent dehydrogenases in lymphocytes of peripheral blood in Graves’ disease
    Margarita A. Dudina et al, 2020, Problems of Endocrinology CrossRef
13. Evaluation of the Abbott Alinity i Thyroid-Stimulating Hormone Receptor Antibody (TRAb) Chemiluminescent Microparticle Immunoassay (CMIA)
    Deborah J. W. Lee et al, 2023, Diagnostics CrossRef
14. Optimal iodine supplementation during antithyroid drug therapy for Graves’ disease is associated with lower recurrence rates than iodine restriction
    Huibin Huang et al, 2018, Clinical Endocrinology CrossRef
15. Thyrotropin receptor antibodies and a genetic hint in antithyroid drug-induced adverse drug reactions
    Lin-Chau Chang et al, 2018, Expert Opinion on Drug Safety CrossRef
16. Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves’ disease: a cross-sectional study
    Masahito Katahira et al, 2023, Hormones CrossRef
17. A systematic review and meta-analysis of the etiology and treatment patterns of thyrotoxicosis in Africa
    Taoreed Adegoke Azeez et al, 2022, Expert Review of Endocrinology & Metabolism CrossRef
18. The relationship between atherosclerotic disease and relapse during ATD treatment
    Xinxin Zhu et al, 2022, Frontiers in Cardiovascular Medicine CrossRef
19. The Recurrence Rate of Graves' Disease among Patients with Subclinical Thyrotoxicosis after Initial Remission with Antithyroid Agents
    Myoung Sook Shim et al, 2017, International Journal of Thyroidology CrossRef
20. Treatment of Grave’s Disease in Adults
    Mauricio Alvarez Andrade et al, 2021, Graves' Disease CrossRef
21. Therapeutic Options in Graves’ Hyperthyroidism
    Javaid Ahmad Bhat et al, 2023, Hyperthyroidism - Recent Updates CrossRef
22. Risk Factors for the Relapse of Graves’ Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis
    He Shi et al, 2020, Clinical Therapeutics CrossRef
23. High levels of thyroid hormones promote recurrence of Graves' disease via overexpression of B‐cell‐activating factor
    Shu Liu et al, 2022, Journal of Clinical Laboratory Analysis CrossRef